Earnings ·
Stereotaxis reported second quarter 2026 revenue of $7.7 million, a decline from $8.8 million in the prior year period
STXSStereotaxis, Inc.
Stereotaxis reported second quarter 2026 revenue of $7.7 million, a decline from $8.8 million in the prior year period. System revenue fell to $1.5 million due to the absence of robotic system deliveries, while recurring revenue rose to $6.2 million, driven by new robotic catheter sales that surpassed $1 million and initial Synchrony digital operating room system sales following FDA clearance. The company completed its acquisition of Robocath, strengthening its endovascular robotics portfolio. Operating loss widened to $4.6 million compared to $4.0 million in the prior year, with a net loss of $4.5 million. Cash and cash equivalents stood at $10.5 million with no debt. Management anticipates recurring revenue growth to approximately $7 million in Q3 and $8 million in Q4 2026, targeting cash flow profitability in the first half of 2027. Stereotaxis operates in the medical device industry, specializing in surgical robotics for minimally invasive endovascular interventions.